论文部分内容阅读
目的观察多西他赛联合顺铂一线治疗晚期非小细胞肺癌的疗效和不良反应。方法67例晚期非小细胞肺癌患者入组。多西他赛75mg/m2,d1,顺铂25mg/m2,d1～3。21d为一个周期。观察临床缓解率、1年生存率和中位生存期。结果该方案的客观有效率为43.8%(28/64),毒副反应主要为恶心、呕吐和骨髓抑制,mTTP为5.4个月,1年生存率为45.3%(29/64),中位生存期为11.2个月。结论多西他赛联合顺铂一线治疗晚期NSCLC更能体现其价值。
Objective To observe the efficacy and side effects of docetaxel plus cisplatin in the treatment of advanced non-small cell lung cancer. Methods 67 cases of advanced non-small cell lung cancer patients. Docetaxel 75mg / m2, d1, cisplatin 25mg / m2, d1 ~ 3.21d for a cycle. Clinical remission rate, 1-year survival rate and median survival time were observed. Results The objective response rate was 43.8% (28/64). The main side effects were nausea, vomiting and myelosuppression. The mTTP was 5.4 months, and the 1-year survival rate was 45.3% (29/64). The median survival rate The period is 11.2 months. Conclusion Docetaxel plus cisplatin in the treatment of advanced NSCLC can reflect its value.